SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing strong momentum following rapid international approvals for Anktiva in the EU and Saudi Arabia, with the community actively anticipating a significant short squeeze fueled by high short interest and growing confidence in global revenue generation from Dr. Soon-Shiong's cancer-curing platform.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to recent announcements of its advanced GaN and SiC power platforms aimed at next-gen AI data centers and its positioning within NVIDIA's AI ecosystem. The community is actively discussing the immense potential of its technology while simultaneously expressing significant concern over the absence of definitive, revenue-generating contracts amidst anticipation for its earnings call.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after announcing positive Phase 2 S-OLARIS trial results in axial spondyloarthritis, with its drug sonelokimab showing an 81% response rate and potential for disease modification, fueling expectations for a major re-rating and potential short squeeze ahead of its Investor Day.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is gaining attention following its AI division joining the NVIDIA Inception Program and widespread adoption of its Intents technology for cross-chain integrations. The community is actively discussing its growing user base, recent tokenomics improvements, and its strategic positioning in the evolving AI and blockchain landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly awaits its imminent BLA resubmission for deramiocel, with high expectations for a significant rally and potential buyout given its "life-saving" potential for Duchenne Muscular Dystrophy patients. Further discussions highlight optimism for accelerated approval, especially amidst evolving FDA policies and widespread calls for regulatory clarity in the rare disease space.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid its decision to halt plans for a business separation and commit a $600M investment to a U.S. turnaround, a strategy lauded by major shareholder Berkshire Hathaway; however, community discussion remains polarized between strong dividend and value appeal versus concerns over mixed earnings and consumer shifts to private labels impacting the broader food sector.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is experiencing a significant surge, driven by extreme cold weather and widespread winter storms across the US, leading to massive heating demand, production disruptions, and historic trading volumes. While many anticipate further gains from continued storage draws, a strong contingent cautions that warmer weather is approaching, highlighting natural gas's well-known volatility and the potential for a swift reversal.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is experiencing heightened volatility as traders grapple with escalating geopolitical tensions in the Middle East that could impact LNG transit, juxtaposed with uncertain late-winter weather patterns and the complexities of natural gas futures contract rollovers. The community is sharply divided, with bulls betting on a short squeeze driven by supply concerns and growing AI data center demand, while bears emphasize robust production and the leveraged ETF's inherent decay.

Memecoin on Injective taken over by the community.

Nonja

NONJA is trending with notable recent gains, as its strong community actively accumulates, confident in its status as a resilient, unruggable meme poised for massive upside due to its deep connection with the fundamentally strong and undervalued Injective ($INJ) ecosystem.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

OKLO is trending amidst fierce debate, with bulls emphasizing its strategic role in powering AI data centers, highlighted by its Meta partnership, anticipated DOE plutonium awards, and recent news of global SMR deals and AI infrastructure investments. Conversely, skeptics point to its pre-revenue status, insider selling, and long commercialization timelines, questioning its current valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat...

Why Is Candel Therapeutics Stock Falling Friday?

Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therapies and development costs.read more...

Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers Grail, Candel Therapeutics, Copart In Focus

U.S. stock futures rose on Friday after closing lower on Thursday. Futures of all the major benchmark indices were positive. Wall Street is waiting for the fourth-quarter GDP data, scheduled for...

<ul class="summary-bullets"><li>The $100 million equity raise is expected to fund commercialization preparations for CAN-2409 in early-stage, localized prostate cancer.</li><li>Candel also plans to use part of the funds to support the ongoing phase 3 trial of CAN-2409 in non-small cell lung cancer.</li><li>RTW is set to receive a tiered single-digit percentage of U.S. net sales, subject to a cap.</li></ul>Shares of Candel Therapeutics, Inc. (CADL) fell 14% in extended trading on Thursday, after the company outlined plans for a $100 million public stock offering, outweighing a $100 million royalty funding agreement announced the same day.<h2 class="st-heading-2">Candel Launches $100M Public Offering</h2>Candel said it has launched an underwritten public offering of $100 million of its common stock. The underwriters have also been granted a 30-day option to purchase up to an additional $15 million in shares on the same terms.According to the company, the proceeds will go toward preparing for the potential launch of Aglatimagene Besadenovec, also known as CAN-2409, in early-stage, localized prostate cancer. This includes medical affairs, launch readiness and other commercialization-related work. Candel also plans to use part of the funds to support the ongoing phase 3 trial of CAN-2409 in non-small cell lung cancer.<h2 class="st-heading-2">RTW Royalty Deal Adds $100M In Funding</h2>Earlier in the day, Candel separately disclosed a $100 million royalty funding agreement with funds managed by RTW Investments. The deal will support a potential U.S. launch of CAN-2409 in intermediate to high-risk localized prostate cancer.The royalty financing is tied to regulatory progress. It will become available upon approval of CAN-2409 by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, RTW would receive a tiered single-digit percentage of annual U.S. net sales of the therapy, subject to a cap.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CADL was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cadl_ss_png_cea4ebff8f.webp" alt="cadl ss.png" width="977" height="147"><figcaption>CADL sentiment and message volume as of February 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Araman44/message/645398070">said</a>, “At the end of the day, this stock has lots of potential due to its pipeline. Trade away as needed. Just don’t be surprised when it flies.”<stembedurl>https://stocktwits.com/Araman44/message/645398070</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/CO145/message/645397862">said</a> they want to see RTW participate in the deal alongside other “prominent” biotech investors, including Manning and “high-quality” institutional funds such as T. Rowe Price. “If we see this, the stock will perform well finally. I do not want to see CVI, Susquehanna, or any of these low-quality players,” they added.<stembedurl>https://stocktwits.com/CO145/message/645397862</stembedurl>CADL stock has risen 5% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CADL stock has risen 5% so far this year. (Photo credit: Getty Images)

Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today

Candel is pushing ahead with an equity raise and also lined up $100 million in royalty funding from RTW Investments, contingent on FDA approval of CAN-2409.

Equity

Candel Therapeutics (NASDAQ:CADL) Trading 3.9% Higher - Should You Buy?

Candel Therapeutics (NASDAQ:CADL) Trading Up 3.9% - What's Next...

Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research

Zacks Research cut shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday...

New Strong Sell Stocks for January 20th

DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports...

Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position

Acorn Capital Advisors LLC boosted its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 19.9% in the second quarter, according to the company in its most recent Form 13F filing...

Brookline Capital Management Weighs in on CADL Q4 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Tech stocks

Energy

Cash / Bonds

Crypto

What&#39;s your biggest portfolio allocation right now?

Stocktwits

What's your biggest portfolio allocation right now?

Stocktwits Polls

Intense discussions surround the CEO's leadership, with sharp criticisms of financing decisions and perceived strategic blunders, alongside defenses of his long-term vision.

Discussion centers on the recent $100M public offering and a non-dilutive $100M royalty deal, fueling debate over management's capital strategy and potential shareholder dilution.

Traders are actively monitoring significant short volume and a recently activated short sale restriction, leading to speculation about a potential price rebound or "squeeze".

Concern mounts over the company's decision to self-commercialize its lead asset, with many investors highlighting the historical low success rates for small biotechs in oncology.

Long-term investors are projecting multi-billion dollar buyout scenarios and comparing the company's market capitalization to peers with approved assets, anticipating significant upside.

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADLCandel Therapeutics Inc